CMV Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T Cell Therapy

Investigators prospectively enrolled 72 adult cytomegalovirus (CMV)-seropositive CD19-, CD20-, or BCMA-targeted chimeric antigen receptor-modified T cell immunotherapy (CARTx)-recipients and tested plasma for CMV pre- and weekly up to twelve weeks post-CARTx.
[Clinical Infectious Diseases]
AbstractGraphical Abstract

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News